Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Loading...
Community
/
Germany
/
Pharmaceuticals & Biotech
/
SCHOTT Pharma KGaA
1SXP
SCHOTT Pharma KGaA
Intensifying Climate Mandates And Protectionism Will Erode Prospects
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 12 Analysts
Published
02 Jul 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
€22.00
6.4% overvalued
intrinsic discount
16 Aug
€23.40
1Y
-27.6%
7D
1.5%
Loading
1Y
-27.6%
7D
1.5%
Author's Valuation
€22.0
6.4% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
€22.0
6.4% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
1b
2020
2021
2022
2023
2024
2025
2026
2027
2028
Revenue €1.2b
Earnings €209.4m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
9.06%
Life Sciences revenue growth rate
0.32%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
5.22%
Calculation
€209.37m
Earnings '28
x
19.34x
PE Ratio '28
=
€4.05b
Market Cap '28
€4.05b
Market Cap '28
/
160.09m
No. shares '28
=
€25.29
Share Price '28
€25.29
Share Price '28
Discounted to 2025 @ 5.22% p.a.
=
€21.71
Fair Value '25